Intensive immunosuppressive therapy for ALL does not suppress anti MV IgG production in patients on the UKALL14 trial. (A) Graph showing anti-MV IgG titer (y-axis) as quantified by enzyme-linked immunosorbent assay. Paired sera from 16 patients participating in the UKALL14 trial were evaluated at a minimum of 2 time points (x-axis). Each dot represents a value, with a line connecting each patient’s individual values. The dotted line represents the level at which a human is considered immune to measles virus infection. (B) Graph showing individual values with mean (horizontal line) and standard error of the mean (SEM; error bars) of anti-MV IgG (y-axis) for the 12 patients with samples from the earliest (day 3 of therapy) and latest time points (after 3 months of intensive inpatient therapy). There is no significant difference between the 2 time points.